000 05369cam a2200577Ki 4500
001 9780429399039
003 FlBoTFG
005 20220724194431.0
006 m o d
007 cr |n|||||||||
008 200913s2021 si o 000 0 eng d
040 _aOCoLC-P
_beng
_erda
_cOCoLC-P
020 _a0429677901
_qelectronic book
020 _a9780429677892
_qelectronic book
020 _a0429677898
_qelectronic book
020 _a9780429677885
_qelectronic book
020 _a042967788X
_qelectronic book
020 _a9780429399039
_qelectronic book
020 _a0429399030
_qelectronic book
020 _a9780429677908
_q(electronic bk.)
020 _z9789814800327
_qhardcover
020 _z9814800325
_qhardcover
035 _a(OCoLC)1194960602
_z(OCoLC)1195441736
035 _a(OCoLC-P)1194960602
050 4 _aR857.N34
_bN36 2021eb
072 7 _aMED
_x009000
_2bisacsh
072 7 _aSCI
_x010000
_2bisacsh
072 7 _aTBN
_2bicssc
082 0 4 _a610.28
_223
245 0 0 _aNano-enabled medical applications /
_cedited by Lajos P. Balogh.
264 1 _aSingapore :
_bJenny Stanford Publishing Pte. Ltd.,
_c[2021]
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aNanomedicine's most cited ;
_vvolume 2
505 0 _aCover -- Half Title -- Series Page -- Title Page -- Copyright Page -- Contents -- Preface -- 1 Intelligent Nanomaterials for Medicine: Carrier Platforms and Targeting Strategies-State of the Art -- 1.1 Introduction -- 1.2 Nanotechnology Carrier Platforms Suited for Switch Functionality -- 1.2.1 Micelles and Liposomes -- 1.2.2 Polymeric Systems -- 1.2.3 Dendrimers -- 1.2.4 Carbon Nanotubes -- 1.2.5 Metallic Nanoparticles -- 1.2.6 Other Organic Nanoparticles: Carbohydrate-Based NPs, e.g., Chitosan and Starch -- 1.2.7 Quantum Dots and Carbon Quantum Dots -- 1.2.8 Nanogels
505 8 _a1.2.9 Peptide-Based Nanoparticles as Delivery System -- 1.3 Advanced Functionality Including Internal and External Stimuli-Responsiveness -- 1.4 Engineering Cell and Tissue Interaction at the Nanoscale -- 1.4.1 Targeting Strategies -- 1.4.1.1 Passive targeting -- 1.4.1.2 Active targeting -- 1.4.2 Endocytotic Cellular Uptake -- 1.4.3 Cellular Uptake by Cell-Penetrating Peptides -- 1.4.4 Endosomal Escape -- 1.4.5 Exocytosis -- 1.5 Clinical Application of Nanomaterials -- 1.5.1 The Clinical Trial Landscape: An Emphasis on Cancer
505 8 _a1.5.2 Potential Risk Factors Regarding Approved Nanoparticle-Based Therapies -- 1.6 Conclusions and Outlook -- 2 Nanocarriers as an Emerging Platform for Cancer Therapy -- 2.1 Passive and Active Targeting -- 2.2 Types of Targeting Agents -- 2.3 The Arsenal of Nanocarriers -- 2.4 The Challenges of Multidrug Resistance -- 2.5 Into the Future -- 3 Microfluidic Technologies for Accelerating the Clinical Translation of Nanoparticles -- 3.1 Well-Controlled Synthesis of Nanoparticles -- 3.2 Evaluation and Screening of Nanoparticles -- 3.3 Future Prospects -- 4 Theranostic Nanomedicine
505 8 _a4.1 Introduction -- 4.2 Imaging Drug Delivery -- 4.3 Imaging Drug Release -- 4.4 Imaging Drug Efficacy -- 4.5 Conclusions -- 5 The Emerging Field of RNA Nanotechnology -- 5.1 Significance and Uniqueness of RNA Nanotechnology -- 5.2 Distinct Attributes of RNA inside the Body -- 5.3 Techniques for Constructing RNA Nanoparticles -- 5.4 Applications of RNA Nanotechnology -- 5.5 Challenges and Perspectives -- 6 Drug Targeting to Tumors: Principles, Pitfalls and (Pre-) Clinical Progress -- 6.1 Introduction -- 6.2 Principles of Drug Targeting to Tumors -- 6.2.1 Passive Targeting
505 8 _a6.2.2 Active Targeting to Cancer Cells -- 6.2.3 Active Targeting to Endothelial Cells -- 6.2.4 Triggered Drug Delivery -- 6.3 Pitfalls in Drug Targeting to Tumors -- 6.3.1 Extravasation and the EPR Effect -- 6.3.2 Penetration -- 6.3.3 Active Targeting -- 6.3.4 Formulation -- 6.3.5 Efficacy vs. Toxicity -- 6.3.6 Metastasis -- 6.3.7 Personalization -- 6.3.8 Translation -- 6.4 (Pre-) Clinical Progress -- 6.5 Conclusion -- 7 Biomolecular Coronas Provide the Biological Identity of Nanosized Materials -- 7.1 Nanoscale Engagement with Biological Processes
520 _aThis book is the second in a series presenting articles that received the most citations in recent years in nanomedicine. The series is edited by, a prominent nanotechnology researcher and editor-in-chief of Precision Nanomedicine. The theme of the second volume is about nano-enabled medical applications. The 19 articles collected here have already acquired more than 12,500 citations highlighting the importance and professional recognition of the work of these scientists in nanomedicine. The content includes the general overview of the field and a wide variety of applications that have been impossible without nanoscience and nanotechnology.
588 _aOCLC-licensed vendor bibliographic record.
650 0 _aNanomedicine.
650 7 _aMEDICAL / Biotechnology
_2bisacsh
650 7 _aSCIENCE / Biotechnology
_2bisacsh
700 1 _aBalogh, Lajos P.,
_eeditor.
856 4 0 _3Read Online
_uhttps://www.taylorfrancis.com/books/9780429399039
856 4 2 _3OCLC metadata license agreement
_uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
942 _2lcc
_cEBK
999 _c17550
_d17550